Skip to content

5-MeO-DMT: all studies

Page 74 of 110: studies 731 to 740 of 1,097, newest first. Back to the 5-MeO-DMT overview

Research

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice

Translational Psychiatry February 23, 2022 Trevor Sharp, Christopher W. Thomas, Cristina Blanco-Duque et al. 40 citations

Abstract Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood. Growing evidence suggests that a single psychedelic experience can positively impact long-term psychological well-being, with relevance for the treatment of psychiatric disorders, including depression. A...

DOI: 10.1038/s41398-022-01846-9 (opens in new tab) Full text (opens in new tab) Sleep architecture Sleep system call Schizophrenia object-oriented programming Electroencephalography +3

The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)

Journal of Neurochemistry February 12, 2022 Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo et al. 108 citations

Abstract 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) is a naturally occurring tryptamine that primarily acts as an agonist at the 5‐HT1A and 5‐HT2A receptors, whereby affinity for the 5‐HT1A subtype is highest. Subjective effects following 5‐MeO‐DMT administration include distortions in auditory and time perception, amplification of emotional states, and feelings of ego dissolution that...

DOI: 10.1111/jnc.15587 (opens in new tab) Anxiety Agonist Depression economics Pharmacology +1

Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine

Expert Opinion on Investigational Drugs February 1, 2022 Lynnette A. Averill, Chadi G. Abdallah

The unfortunate reality of the mental health crisis plaguing much of the world, in tandem with and exacerbated by the COVID-19 pandemic [1–3], highlights the limited effective pharmacologic treatments in our toolbox for posttraumatic stress disorder (PTSD). There are only two FDA-approved medications indicated for PTSD, both selective serotonin reuptake inhibitors (SSRIs). Though these...

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

Frontiers in Pharmacology January 27, 2022 Athanasios Markopoulos, Antonio Inserra, Danilo de Gregorio et al. 44 citations

Recent clinical and preclinical evidence points towards empathogenic and prosocial effects elicited by psychedelic compounds, notably the serotonin 5-HT 2A agonists lysergic acid diethylamide (LSD), psilocybin, N,N-Dimethyltryptamine (DMT), and their derivatives. These findings suggest a therapeutic potential of psychedelic compounds for some of the behavioural traits associated with autism...

Analysis of recreational psychedelic substance use experiences classified by substance

Psychopharmacology January 15, 2022 Adrian Hase, M Erdmann, Verena Limbach et al. 33 citations

Abstract Rationale and objectives Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states...

Pharmahuasca and DMT Rescue ROS Production and Differentially Expressed Genes Observed after Predator and Psychosocial Stress: Relevance to Human PTSD.

ACS Chemical Neuroscience January 6, 2022 D. Kelley, Katy Venable, Aspasia Destouni et al. 41 citations

Post-traumatic stress disorder (PTSD) is associated with cognitive deficits, oxidative stress, and inflammation. Animal models have recapitulated features of PTSD, but no comparative RNA sequencing analysis of differentially expressed genes (DEGs) in the brain between PTSD and animal models of traumatic stress has been carried out. We compared DEGs from the prefrontal cortex (PFC) of an...

The White Sun of Substance: Spinozism and the Psychedelic amor Dei intellectualis

Bloomsbury Academic eBooks 2022 Peter Sjöstedt-hughes 27 citations

Experiences of enlightened unity with Nature or with Deity are reported not only in the mystical literature of the past but also in contemporary accounts of the psychedelic adventurer. In Chapter 13, Peter Sjöstedt-Hughes seeks to fathom such reported states within the framework of the metaphysics of Benedict de Spinoza – a metaphysics encompassing monism, pantheism, panpsychism, and the...

Ayahuasca for the Treatment of Depression.

Current Topics in Behavioral Neurosciences 2022 Fernanda Palhano-Fontes, Bruno Lobão‐soares, Nicole Leite Galvão‐coelho et al. 25 citations

Ayahuasca, the vine of the souls in Quechua, is a psychedelic brew with a few formulations that most often include the bark of a liana in the Malpighiaceae family (Banisteriopsis caapi), with leaves from a shrub in the coffee family Rubiaceae (Psychotria viridis). Mixed with water and boiled for hours or days, it produces a brownish-colored liquid with a strong and characteristic taste....

Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation

Current Topics in Behavioral Neurosciences 2022 Matthew W. Johnson 31 citations

This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about...

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.

International Journal of Drug Policy 2022 Brian S. Barnett, Sloane E Parker, Jeremy Weleff 57 citations

Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistently demonstrated promising findings for psychedelic-assisted therapies in the treatment of various mental health conditions and addictions. While most of this work has been privately funded, governmental biomedical research funding bodies in countries...